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Abstract
A new coronavirus respiratory disease (COVID-19) caused by the SARS-CoV-2 virus, surprised the entire world,
producing social, economic, and health problems. The COVID-19 triggers a lung infection with a multiple
proinflammatory cytokine storm in severe patients. Without effective and safe treatments, COVID-19 has killed
thousands of people, becoming a pandemic. Stem cells have been suggested as a therapy for lung-related diseases.
In particular, mesenchymal stem cells (MSCs) have been successfully tested in some clinical trials in patients with
COVID-19. The encouraging results positioned MSCs as a possible cell therapy for COVID-19. The amniotic
membrane from the human placenta at term is a valuable stem cell source, including human amniotic epithelial
cells (hAECs) and human mesenchymal stromal cells (hAMSCs). Interestingly, amnion cells have immunoregulatory,
regenerative, and anti-inflammatory properties. Moreover, hAECs and hAMSCs have been used both in preclinical
studies and in clinical trials against respiratory diseases. They have reduced the inflammatory response and restored
the pulmonary tissue architecture in lung injury in vivo models. Here, we review the existing data about the stem
cells use for COVID-19 treatment, including the ongoing clinical trials. We also consider the non-cellular therapies
that are being applied. Finally, we discuss the human amniotic membrane cells use in patients who suffer from
immune/inflammatory lung diseases and hypothesize their possible use as a successful treatment against COVID-19.
Keywords: COVID-19, SARS-CoV-2, Stem cells, Stem cell therapy, Mesenchymal stem cells, Amnion, Human amniotic
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Introduction
The COVID-19 (coronavirus disease-2019) is a new re-
spiratory disease caused by the SARS-CoV-2 (severe
acute respiratory syndrome coronavirus 2) virus. This
virus was identified in several pneumonia patients in late
December 2019 in Wuhan city, Hubei province, in
China. Since then, the COVID-19 contagion has oc-
curred exponentially worldwide, becoming the most ur-
gent problem of global public health [1, 2].
Such was the level of spread and severity of the disease
that on March 11, 2020, the WHO (World Health
Organization) decided to declare it as a pandemic dis-
ease [2]. By December 21, 2020, approximately 77 mil-
lion people were infected and more than 1.6 million
deaths from COVID-19 have been reported. The global
mortality due to COVID-19 oscillates between 2 and
10% approximately.
The COVID-19 is characterized by a lung infection
that in several cases can trigger a multiple proinflamma-
tory cytokine storm. This cytokine storm causes different
lung traumas including air exchange dysfunction, edema,
acute respiratory distress, and secondary infection.
Moreover, pre-existing comorbidities, older age, and
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male sex are the major risk factors for complications.
These conditions could result in death, without effective
treatment [3, 4].
Since its appearance, different biomedicine experts
from all over the world mobilized to discover a treat-
ment to control this pandemic disease. Therefore, the
recent outbreak of COVID-19 highlights the urgent need
for safe and effective therapies, especially for the most
severe cases.
Stem cells have always been a focus of attention for re-
generative medicine and cellular therapies. Mesenchymal
stem cells (MSCs) in particular have low immunogen-
icity, appreciable differentiation capability, and outstand-
ing immunomodulatory properties [5]. Moreover, MSCs
can oppose viral infection because of their enhanced
cytokine quality production. MSCs are present in almost
all tissues, and their properties and characteristics are
different depending on the tissue. Properties of stem
cells isolated from the human placenta are unique since
they are easy to obtain without invasive procedures and
have no ethics concerns. In addition, stem cells from the
amniotic membrane are obtained in large quantities,
they are not tumorigenic, and they can be used in allo-
genic transplants [6]. Based not only on their strong im-
munomodulatory properties but also due they mainly
accumulate in the lung, experts began to consider MSCs
as a promising source of COVID-19 therapy. In fact,
many clinical trials have been elicited.
Here, we review and discuss the general characteristics
of COVID-19, the current clinical trials with MSCs, and
the possible therapeutic options using the human amni-
otic membrane stem cells.
Coronavirus and COVID-19: characteristics and
mechanisms of infection
Viruses are acellular infectious particles containing ei-
ther RNA or DNA (single- or double-stranded) that can
infect all life forms.
Coronaviruses (CoVs) are a group of enveloped viruses
with a non-segmented positive-sense RNA genome, of
approximately 30 kb. The CoVs have a spherical shape
with a solar corona appearance. This appearance results
from the presence of a lipid envelope studded with spike
projections that emanate from the virus surface [7].
The SARS-CoV-2 virion measures 60–140 nm with
club-shaped glycoprotein spikes on the surface and 10
ORFs. These ORFs encode the complete viral genome,
including the replicase polyprotein 1ab and the viral
structural proteins (membrane, envelope, spike, nucleo-
capsid and auxiliary proteins) [8] (Fig. 1a).
The SARS-CoV-2 virus data would indicate that the
most likely primary source of COVID-19 would be the
bats [9]. However, it is not known yet whether there is
an intermediate host between bats and humans [10].
The contagion rate and the transmissibility are very
high. Most of the evidence proposes that the transmis-
sion of SARS-CoV-2 between humans occurs when an
infected person coughs, sneezes, talks, or sings [11].
The host infection SARS-CoV-2 mechanism consists
in the spike glycoprotein (S) binding to receptor 2 of the
angiotensin-converting enzyme I (ACE2) [12]. This re-
ceptor is expressed in almost all organs of the body, es-
pecially in alveolar type II cells that produce surfactant
factor [13–15]. The SARS-CoV-2 also enters the cells via
a pH-dependent endocytosis, mechanism, and involving
the proteases accessibility in the host. Cathepsins, furin,
TMPRSS2, and human airway trypsin-like protease
(HAT) control CoVs entrance to the cells through the
plasma membrane or endocytosis. The cellular serine
protease TMPRSS2 is required to correctly process the
SARS-CoV-2 spike protein and facilitate the host cell
entry [15] (Fig. 1b).
Pathology development
Once hCoV invades host cells, it activates the innate im-
mune system. The immunity system triggers a release of
inflammatory factors that limits the expansion of the
virus and stimulates its phagocytosis by macrophages.
However, SARS-CoV-2 can evade the innate immune re-
sponse, mainly by increasing the number of copies in
the airway epithelium [16]. Then, the adaptive immune
response, mediated by B and T lymphocytes, activates
the production of hCoV-specific antibodies, and the re-
lease of proinflammatory cytokines, respectively [17, 18].
The regulation of the antibody response in patients in-
fected with SARS-CoV-2 is largely unknown.
It is estimated that 81% of patients infected with
SARS-CoV-2 suffer from mild or asymptomatic disease.
The most common symptoms in these cases are fever,
fatigue, dry cough, and shortness of breath. On the other
hand, 14% of patients manifest severe conditions.
Among these cases, it is calculated that 20% are patients
with diabetes, 15% with hypertension, and 15% with
other cardiovascular diseases. All severe patients develop
pneumonia [19]. In general, this pneumonia is evidenced
by bilateral patchy shadows or ground-glass opacity
(GGO) in computed tomography (CT) lung scans. The
rest of the patients suffers from a serious illness featured
by severe pneumonia with respiratory insufficiency. This
respiratory condition triggers in a short period the acute
respiratory distress syndrome (ARDS), septic shock, and
multiorgan dysfunction [20, 21].
The ARDS is characterized by an overreaction of the
immune system. The result is a massive inflammatory
cell infiltration and the release of pro-inflammatory cy-
tokines and chemokines including interleukin (IL)-6, IL-
8, IL-1β, interferon-gamma (IFN-γ), granulocyte colony-
stimulating factor (GSCF), monocyte chemo-attractant
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protein 1 (MCP1), macrophage inflammatory protein 1
alpha and 1 beta (MIP1A, MIP1B), tumor necrosis
factor-alpha (TNF-α), CCL-2, CCL-3, CCL-5, and inter-
feron γ inducible protein (IP-10) [19, 22]. These proteins
attract macrophages, monocytes, and T cells to the in-
fection site promoting additional inflammation and be-
ginning a pro-inflammatory feedback loop. Thereby, the
malfunctioning immune response conduces to further
accumulation of immune cells in the lungs. This accu-
mulation triggers a pro-inflammatory cytokine overpro-
duction which eventually damages the lung structure
[23]. Like in other coronavirus infections, during
COVID-19 there is an attempt to repair and remodeling
the lungs by fibroproliferation. This derives in a poten-
tial risk of developing pulmonary fibrosis, which in fact
may occur as a consequence of SARS-CoV-2 infection.
Fibrotic sequelae are found in CT lung scans in COVID-
19 patients [24].
The origin of the cytokine storm triggered by the cor-
onavirus occurs in the infected area and rapidly expands
through the central body circulation. This cytokine
storm spreads throughout the body, causing the decline
of patient condition and producing, in most cases, its
death due to multiorgan failure [25].
Severe affected people age goes from 60 years and over
probably due to a dysfunctional immune response devel-
opment and/or a failure in virus elimination [26]. On
the other hand, most of the children younger than 18
years are asymptomatic or develop mild symptoms [27].
In this context, the set of immune factors that lead to a
severe inflammatory response are still unclear, and con-
sequently possible treatments are also uncertain (Fig. 2).
Fig. 1 SARS-CoV-2 structure and cell entry. a The coronavirus (CoVs) structure is complex and includes the three principal structural proteins: the
spike glycoprotein (S), the transmembrane glycoprotein (M), and the nucleocapsid protein (N). The glycoprotein S is found in the viral envelope.
The envelope (E) protein is a minor transmembrane protein present in the structural region. The CoVs genome is formed by a positive sense
single-stranded RNA of 30 kb in size. b As a coronavirus, SARS-CoV-2 uses the S glycoprotein to facilitate entry to the host cell. This virus
principally targets the respiratory epithelial cells, that express the angiotensin-converting enzyme 2 receptor (ACE2). The S protein binds to ACE2
allowing the virus access to the host cells cytosol. Proteases like TMPRRS2, cathepsin, or furin, help to viral and cellular membranes fusion through
the S protein cleavage. After the viral entry, the replicase gene from the virion genomic RNA is translated. Then, the viral RNA is synthesized and
the replicase complexes assembly. In the endoplasmic reticulum occurs the translation of the structural glycoproteins S, M, and E. All the
translated proteins interact for CoVs assembling. Once the virions are formed, they are transported to the host cell surface in vesicles and then
released by exocytosis. (This figure was created with BioRender.com)
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Stem cell therapies for COVID-19
Stem cell contribution to current medicine is central,
both for their use in basic research, and for the oppor-
tunities to develop innovative therapies in clinical prac-
tice. The urgency of finding new and effective
treatments against COVID-19 has positioned stem cells
at a strategic place in the scene. Since COVID-19
emerged, several groups have dedicated their efforts to
this topic. In this way, Han et al. [28] have derived lung
organoids from human-induced pluripotent stem cells in
order to analyze COVID-19 consequences and possible
drug treatments. The alveolar type II cells from the
organoids expressed ACE2 and were susceptible to virus
infection. They also tested the potential of virus
infection in mouse xenografts models. In both cases, the
presence of SARS-CoV-2 virus was detected after 24 h
of infection. This group identified some drug candi-
dates—approved by the Food and Drug Administration
(FDA)—that were able to block the RNA virus replica-
tion: imatinib, mycophenolic acid, quinacrine dihy-
drochloride, chloroquine, and prochlorperazine. They
provided evidence that support the use of these drugs in
clinical trials.
In addition, as the adipose stem cells (ASC) and the
stromal vascular fraction (SVF) possess a high secretory
activity of proangiogenic factors and immunomodulatory
properties, they have been considered for COVID-19 pa-
tient treatment. Indeed, both ASC and SVF, as well as
Fig. 2 Perspectives of amniotic membrane stem cell therapy against COVID-19. Stem cells isolated from the amnion of the human placenta at
term include hAECs and hAMSCs. HAMSCs and hAECs have immunoregulatory, anti-inflammatory, and regenerative properties. These features
position amniotic stem cells as candidate for a successful treatment against COVID-19. The amniotic membrane stem cell therapy could attenuate
the cytokine storm that occurs in acute respiratory distress syndrome (ARDS) caused by the SARS-CoV-2 virus. Amnion cells could modulate the
proliferation, function, and migration of immune cells such as T and B lymphocytes, NK cells, DC, neutrophils, and macrophages. Thus, hAECs and
hAMSCs would stimulate regulatory immune cells decreasing the pulmonary inflammatory microenvironment. Moreover, amniotic membrane
cells would reduce proinflammatory cytokines (TNF-α, IFN-γ, IL-6, and MCP-1) and increase the release of soluble anti-inflammatory factors (IL-10,
IL-1β, PGE2, MIF, VEGF, and IDO). Additionally, amnion cells could exert an anti-fibrotic effect at the lung injury focus through TGF-β factor
inhibition. Altogether, human amniotic membrane stem cell therapy would prevent multiple organ failure progression in patients who suffer
from COVID-19 (This figure was created with BioRender.com)
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microRNAs derived from ASC, could be injected in
these patients in a quick and safe way [29].
Human embryonic stem cells (hESC) have also been
studied as a possible COVID-19 treatment, for lung fi-
brosis condition [30]. In this study, authors demon-
strated that MSCs like derived from hESC are capable to
modulate and regulate extracellular matrix production
in a bleomycin-induced model of lung injury. These cells
also displayed strong immunomodulatory and antifibro-
tic functions, being able to attenuate lung injuries
in vivo. Additionally, their transplantation both in mice
and monkeys have shown an excellent safety profile.
MSCs are the most widely used stem cells in medical
therapies. MSCs are multipotent cells that can be iso-
lated from the bone marrow, adipose tissue, umbilical
cord, dental pulp, and placenta. These cells have immu-
nomodulatory properties that not only protect organs
and tissues from a variety of lesions but also favor their
regeneration. Besides, such properties allow both allo-
geneic and autologous use. Most of MSCs are obtained
in low number, so in vitro expansion is necessary. How-
ever, they have a high proliferation rate which ensures
enough cell quantity for clinical application [9]. More-
over, they release anti-inflammatory, antibacterial, anti-
viral, and immunoregulatory factors, locally in the lesion
site [31, 32]. MSC applications in medicine are quite safe
[33]. Recently, some reviews works have highlighted the
capacity of MSCs to modulate inflammatory response
and consequently to protect from COVID-19 lung injur-
ies [34, 35].
In 2004, the first published report about the clinical
use of MSCs for a pediatric patient with acute refractory
graft-vs-host-disease (GVHD) appeared [36]. Since then,
data relative to MSC immunoregulatory properties have
raised, until reaching approximately one third of current
trials. Most of them are based on CD4 T-lymphocytes,
dendritic cells (DC), and natural killer (NK) cell activity
modulation [37]. After MSCs intravenous delivery, 80–
90% of cells migrate and stay in the lungs. Curiously,
most clinical trials studying MSC effect on lung diseases
were scarce until this year. Nowadays, promising results
are being obtained from preclinical studies and clinical
trials related to several diseases characterized by pre-
dominant inflammation such as ARDS [38–41].
One interesting approach to treat COVID-19 is the
use of exosomes derived from MSCs. Exosomes contain
several chemokines, growth factors, microRNAs, and
mRNA that can exert paracrine and endocrine anti-
inflammatory, anti-fibrotic, regenerative, and immuno-
modulatory effects [42]. Thus, some authors propose
exosomes derived from bone marrow mesenchymal stem
cells (BM-MSC) as a new therapy option for COVID-19.
In their study, Sengupta et al. [43] treated 24 COVID-19
patients with exosomes derived from BM-MSC, and
after 14 days, they observed a survival rate of 83%, with-
out adverse events. In recovered patients, oxygenation
was restored and cytokine storm was inhibited.
Pathologies originated by SARS-CoV-2 in organs and
tissues are multiple and not only limited to respiratory
tract. The immune system exacerbation, cytokine storm,
and pulmonary damage and fibrosis could lead to ARDS,
with a secondary risk of bacterial infection. In addition,
other organs like the liver, heart, brain, kidneys, or gut
could also be affected by COVID-19. In this context, and
given the pleiotropic activities that could exert in this
disease, MSCs should be considered as a potential treat-
ment. The beneficial actions of MSC consist not only of
immunomodulation and anti-inflammation properties,
but also in promoting tissue regeneration and repair
(Table 1). MSC transplantation can reduce the immune
system exacerbation by inhibition of the innate immune
response, the release of immunomodulatory molecules,
and the inhibition of the adaptive immune cell prolifera-
tion and activation [44, 45]. Cytokine storm could be
ameliorated after the release of anti-inflammatory mole-
cules and increase of Treg cells, Th22 cells, and M2
macrophages phenotype [46–48]. Also, MSCs secrete
LL-37 peptide that has an antibacterial effect [32]. MSCs
inhibit TGF-β1 and collagen deposition in the lungs pro-
moting an antifibrotic effect. Moreover, the tissue dam-
age can be repaired since MSCs induce
neovascularization and stem cell differentiation and pro-
liferation [49, 50].
Some cardiovascular pathologies like arrhythmias,
acute coronary syndrome, myocarditis, coagulopathies,
and Kawasaki syndrome were described to be associated
with COVID-19 [51–53]. Either due to their antiapopto-
tic, neoangiogenic, or immunomodulatory effects, MSC
has demonstrated to exert protective actions in several
cardiovascular diseases [54–56]. Similar effects of MSC
and their EVs (extracellular vesicles) have been reported
in acute kidney injury models [57]. The liver has also
been reported to be injured during COVID-19, mainly
by cholestasis and hepatitis [58]. In animal models,
MSCs have improved hepatitis B condition [59]. Scleros-
ing cholangitis was also ameliorated by modulation of
Th cells and reduction of pro-inflammatory molecules
[60]. COVID-19 patients suffered gastrointestinal alter-
ations, including gut microbiota alteration [61]. MSCs
can regulate inflammation and restore composition and
diversity of colonic bacteria [62, 63]. The brain is af-
fected by SARS-CoV-2. When the loss of taste and smell
was detected, the capacity of the virus to invade and
affect the nervous system became in evidence. Actually,
diseases associated with SARS-CoV-2 include stroke,
headache, epileptic seizures, depression, encephalitis,
dizziness, and Guillain-Barre syndrome [64]. Some stud-
ies have shown that MSCs are able to improve these
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conditions mainly by immunomodulation, neuroprotec-
tion induction, angiogenesis promotion, and reduction
of the proinflammatory environment [65–67].
Currently, there are 41 clinical trials using MSCs as
cell therapy to combat SARS-CoV-2 pneumonia. More-
over, 21 of them use MSCs derived from the human pla-
centa (Table 2). Some of them have been completed and
data have been published.
The first clinical trial reported by Liang et al. [68] eval-
uated the use of allogeneic human umbilical cord mes-
enchymal stem cells (hUCMSC) to treat a severe patient
with COVID-19. The 65-year-old patient with severe
pneumonia, and respiratory and multiorgan failure was
intravenously treated with three doses of 5 × 107
hUCMSCs, one dose every 3 days, in combination with
antibiotics and α1-timosin. Previously, the patient had
received a conventional treatment of antiviral, antibi-
otics, glucocorticoids, and immunoglobulins that was in-
effective. After the second administration, negative
serum parameters such as alanine aminotransferase
(ALT), aspartate aminotransferase (AST), C-reactive
protein (CRP), and bilirubin gradually decreased and
other vital signs were stabilized. Also, the number of
white blood cells and neutrophils decreased, and the T
cells subsets increased, all to their normal levels. CT im-
ages showed a significant decrease in the GGO in both
the lungs. After 2 days of the third injection, the patient
was negative for SARS-CoV-2 and discharged with no
Table 1 Pathologies involved in COVID-19 infection and MSC mechanisms to counteract the infection damages
Organs/tissue SARS-CoV-2 associated pathologies Mechanisms of MSC action
Respiratory tract Immune system exacerbation
Cytokine storm




-Inhibit innate immune cell activation (NK, DC, neutrophils, macrophages)
-Inhibit adaptive immune cell proliferation and activation (T and B cells)
-Immunomodulatory molecules release (HGF, IDO, PGE2)
Anti-inflammation
-Anti-inflammatory cytokine release (IL-10, TGF-β)
-Increase Treg and Th22 cells
-Induce M2 macrophages phenotype
Antibacterial effect
-Release antibacterial peptide (LL-37)
Regeneration
-Induce neovascularization
-Stimulate local stem cell differentiation and proliferation
-Secrete angiopoietin-1 and FGF-7
-Increase bioenergetic levels through mitochondrial transfer
Fibrosis reduction







-Reduce IL-1β, IL-12, IL-17, C–C motif chemokine ligand 5, INF-ϒ, and TNF-α levels
-Polarize macrophages towards an anti-inflammatory state
Antiapoptotic effect







Immunomodulation of T helper (Th) cells
Reduction of TNF-α, cytokeratin 19, metallopeptidase 9 and MCP-1
Improvement of monocyte infiltration in bile ducts
Kidneys Acute kidney injury (AKI) Immunomodulation
Inhibition of apoptosis
Promotion of angiogenesis Nephroprotective effects
Regeneration of renal tubular cells through MSC-derived EVs
Digestive tract Gastrointestinal (GI) alterations
Deep alterations in gut microbiota
Inflammation regulation
Induce the restoration of composition and diversity of colonic bacteria
Promote tissue remodeling
Induce eradication of pathogenic bacteria










Re-establishment of neural circuit
Help to reduce viral invasion
Induce reprogramming of microglia from M1 to M2 phenotype
Downregulate TNF-α, IL-1β, and IL-6
HGF hepatocyte growth factor, IDO indoleamine 2,3-dioxygenase, PGE2 prostaglandin E2, TGF-β transforming growth factor β, Treg cells T regulatory cells, Th22
cells T helper cells 22, EVs extracellular vesicles
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Table 2 Clinical trials for COVID-19 treatment using human placenta MSCs
Clinical trial ID Title Cell type Status Phase Outcome measures Locations
NCT04390139 Efficacy and safety evaluation
of mesenchymal stem cells for
the treatment of patients with
respiratory distress due to
COVID-19
WJ-MSCs Recruiting 1; 2 -All-cause mortality at day 28.
-Safety of WJ-MSC.








NCT04456361 Use of mesenchymal stem cells
in acute respiratory distress









NCT04313322 Treatment of COVID-19 patients
using Wharton’s jelly-mesenchymal
stem cells








P-MMSCs Recruiting 1; 2 -Changes in length of hospital stay.
-Changes in mortality rate.
-Evaluation of pneumonia
improvement.
-Peripheral blood count recovery time.
-And 3 more.
Ukraine
NCT04565665 Cord blood-derived mesenchymal
stem cells for the treatment of
COVID-19 related acute respiratory
distress syndrome
CB-MSCs Recruiting 1 -Incidence of composite serious
adverse events.
-Overall survival rate.
-Determine the treatment effect on




NCT04494386 Umbilical cord lining stem cells
(ULSC) in patients with COVID-19
ARDS
ULSCs Recruiting 1; 2 -Incidence of dose limiting toxicity.
-Changes in levels of blood glucose
(mg/dL) from baseline.
-Changes in levels of sodium and
potassium (mEq/L) from baseline.
-And 9 more.
USA
NCT04573270 Mesenchymal stem cells for the
treatment of COVID-19
UC-MSCs Completed 1 -Survival rates.
-Contraction rates
USA
NCT04288102 Treatment with human umbilical
cord-derived mesenchymal stem
cells for severe corona virus disease
2019 (COVID-19)
UC-MSCs Completed 2 -Change in lesion, ground-glass, or
consolidation lesion proportion of full
lung volume from baseline to day 10,
28, and 90.
-Time to clinical improvement.
-And 5 more.
China
NCT04355728 Use of UC-MSCs for COVID-19
patients
UC-MSCs Completed 1; 2 -Incidence of pre-specified infusion
associated adverse events.
-Incidence of severe adverse events.






NCT04252118 Mesenchymal stem cell treatment
for pneumonia patients infected
with COVID-19
UC-MSCs Recruiting 1 -Size of lesion area by
Chest radiograph or CT.
-Time of nucleic acid turning negative.
-CD4+ and CD8+ T cell count.
-And 6 more
China
NCT04416139 Mesenchymal stem cell for acute
respiratory distress syndrome due
for COVID-19
UC-MSCs Recruiting 2 -Changes in body temperature.
-General biochemical changes in
Leukocytes.
-Functional respiratory change: PaO2/FiO2 ratio.
-And 23 more.
Mexico
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Table 2 Clinical trials for COVID-19 treatment using human placenta MSCs (Continued)
Clinical trial ID Title Cell type Status Phase Outcome measures Locations
NCT04437823 Efficacy of intravenous infusions
of stem cells in the treatment
of COVID-19 patients
UC-MSCs Recruiting 2 -Safety and efficacy assessment of infusion
associated adverse events.




NCT04333368 Cell therapy using umbilical
cord-derived mesenchymal
stromal cells in SARS-CoV-
2-related ARDS





-Cumulative use and duration of sedatives.
-And 9 more.
France
NCT04366063 Mesenchymal stem cell therapy
for SARS-CoV-2- related acute
respiratory distress syndrome









NCT04339660 Clinical research of human
mesenchymal stem cells in the
treatment of COVID-19
Pneumonia
UC-MSCs Recruiting 1; 2 -The immune function.
-Blood oxygen saturation.
-Duration of respiratory symptoms.
-COVID-19 nucleic acid negative time.
-And 4 more.
China
NCT03042143 Repair of acute respiratory
distress syndrome by stromal
cell administration (REALIST)
(COVID-19)




-Ventilation free days at day 28.
-And 6 more.
UK
NCT04399889 hCT-MSCs for COVID19 ARDS UC-MSCs Recruiting 1; 2 -Survival after 28 days after the first
dose of MSCs.
-The number of ventilator free days.
-And 8 more.
USA
NCT04269525 Umbilical cord (UC)-derived
mesenchymal stem cells (MSCs)
Treatment for the 2019-novel
coronavirus (nCOV) pneumonia
UC-MSCs Recruiting 2 -Oxygenation index.
-28 days mortality.
-Hospital stays. 2019-nCoV antibody test.
-2019-nCoV nucleic acid test.
-Improvement of lung imaging examinations.
-And 13 more.
China
NCT04366271 Clinical trial of allogeneic
mesenchymal cells from umbilical
cord tissue in patients with
COVID-19 (MESCEL-COVID19)
UC-MSCs Recruiting 2 -Mortality from any cause at 28 days.
-Patients alive and without mechanical
ventilation on day 14.
-Patients cured at 15 days.
-And 8 more.
Spain
NCT04371601 Safety and effectiveness of
mesenchymal stem cells in
the treatment of pneumonia
of coronavirus disease 2019
UC-MSCs Active, not
recruiting
1 -Changes of oxygenation index.





ChiCTR2000031430 Clinical study of human umbilical
cord mesenchymal stem cells in
the treatment of novel coronavirus
pneumonia (COVID-19) induced
pulmonary fibrosis
UC-MSCs Recruiting 2 -Coagulation.






MSCs mesenchymal stromal cells, WJ-MSCs Wharton’s Jelly mesenchymal stem cells, P-MMSCs placenta-derived multipotent mesenchymal stromal cells, CB-MSCs
cord blood-derived mesenchymal stem cells, ULSCs umbilical cord lining stem cells, UC-MSCs umbilical cord mesenchymal stem cells
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side effects. These results suggested that hUCMSC could
be used alone or in combination with other immuno-
modulators as an alternative treatment for severe pa-
tients with COVID-19.
The second clinical trial evaluated the therapeutic po-
tential of transplanted hUCMSCs in 7 patients with
COVID-19 pneumonia [69]. Among the 7 patients, one
presented critical condition, four were in serious condi-
tion, and two had mild symptoms. Other three severe
patients were included in the study with the administra-
tion of placebo as control. All patients had symptoms,
including high fever, shortness of breath, and low oxygen
saturation. Treatment was based on the administration
of a single intravenous infusion of 1 × 106 MSCs per
kilogram bodyweight. After 2–4 days of MSC infusion,
all patients significantly improved lung function and de-
creased clinical symptoms. Moreover, peripheral
lymphocyte levels increased, accompanied by a shift to a
regulatory phenotype of both CD4+ T cells and DC.
Pro-inflammatory cytokines secreting immune cells,
such as CRCR3 CD4+ T cells, CXCR3 CD8+ T cells,
and NK CXCR3 cells decreased from day 3 onwards.
The authors also observed a decrease in TNF-α and an
increase in IL-10 and vascular endothelial-derived
growth factor (VEGF) that correlated with pulmonary
regeneration in treated patients. No adverse effects were
observed in any of the patients after 14 days of treat-
ment. The authors of this study concluded that MSC
intravenous administration significantly improved the in-
flammatory status of COVID-19 severe patients, in a safe
and effective manner. These promising results were
probably due to their immunomodulatory, and anti-
inflammatory capacity, which ameliorated fibrosis and
improved lung function [69].
A similar study [70] reported the recovery of a
COVID-19 severe patient after UCMSCs transplantation.
This trial was performed in China. The patient improved
its situation after 2 days of intravenous cells injection (1
× 106 cells per kilogram of weight). Moreover, 7 days
after treatment the patient was discharged. The proin-
flammatory parameters decreased and regulatory im-
mune cells increased. Thus, UCMSC transplantation was
an effective treatment for a critical COVID-19 patient.
Meng et al. [71] also performed a phase I clinical trial
with UCMSCs in moderate and severe COVID-19 pa-
tients, all of them with pulmonary disease. The trial in-
volved 18 hospitalized Chinese patients, 9 of which
received a treatment with three doses of UCMSC intra-
venous infusion (3 × 107 cells/dose). There were no ad-
verse incidents after UCMSC infusion, except flushing
and fever in two patients and transient hypoxia in one
treated patient. The UCMSC treatment demonstrated to
be safe and well tolerated. However, all patients, treated
or not with the stem cells, were discharged after the
improvement of clinical and laboratory parameters. A
new and bigger phase 2/3 study is being carried out in
order to establish the efficacy of treatment to reduce
deaths.
New clinical trials with a higher number of SARS-
CoV-2-positive patients are needed to validate the safety
and efficacy of hUCMSCs. Similar studies are being car-
ried out with other sources of MSCs, like human dental
pulp or umbilical cord blood; however, no results have
been obtained yet [72–74].
Importantly, as we mention before, iPSC differentiated
to alveolar type II cells are susceptible to be infected by
SARS-CoV-2, in vitro [28]. The intention of this model
was to study the virus biology and to enable drug candi-
dates screening, but it does not appear to be designed
for cell therapy against COVID-19. On the other hand,
it has been demonstrated that MSCs are resistant to
SARS-CoV-2 infection, both in vitro and in vivo. Schäfer
et al. [75] have evaluated the possibility that SARS-CoV-
2 can infect human ASCs and BM-MSCs. This is an im-
portant issue to consider since infection of stem cells
could result in a clearance of transplanted cells impeding
their therapeutic efficiency. Moreover, MSCs infected by
the SARS-CoV-2 could cause undesirable and unknown
side effects, including complications, symptoms aggrava-
tion, or transformation [76]. They tested one condition
without additional stimuli, a second inflammatory condi-
tion and a third condition of co-coculture with virus-
infected cells (Caco-2 cells). Both BM-MSC and ASC
were resistant to virus infection in the three conditions.
First, they observed very low expression of ACE2 and
TMPRSS2 in MSCs under these conditions. They did
not observe virus infection in any of the cases. In
addition, MSCs retained their immunomodulation po-
tential. Amniotic fluid MSC yielded comparable results.
With a similar objective, Leng et al. [69] performed a
clinical trial injecting MSCs in patients with pneumonia
caused by COVID-19. They analyzed gene expression of
transplanted MSCs by RNA-seq, and they demonstrated
that MSCs were negative for ACE2 and TMPRSS2 ex-
pression. This would suggest that MSCs are resistant to
infection by SARS-CoV-2, which make them a promis-
ing candidate to treat COVID-19 patients.
Human amniotic membrane-derived stem cells as
a therapy for respiratory diseases
Advances in regenerative medicine have intensified the
search for new sources of stem cells that can be used as
a therapy for different pathologies, including respiratory
diseases. In recent years, special attention has been paid
to the various types of cells that can be isolated from the
human fetal membranes, now recognized as an abundant
stem cell source with immunoregulatory and regenera-
tive properties [77, 78].
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The fetal membranes are composed of three layers: the
amnion, the chorion, and the decidua capsularis [79].
The amnion is a fetal tissue formed by an epithelial
layer, a collagenous basement membrane, and a stroma
layer between the chorion and the amniotic sac [80].
Two types of stem cells can be isolated from the human
amniotic membrane: the amniotic mesenchymal stromal
cells (hAMSCs), distributed in the collagenous stroma,
and the amniotic epithelial cells (hAECs), which delimit
the amniotic cavity.
Remarkably, hAMSCs and hAECs have unique features
that position them as important candidates for cell ther-
apy. These features include their immunomodulatory
properties, their differentiation potential, their isolation
without ethical questions, their lack of tumorigenicity, and
the possibility of both allogeneic and autologous trans-
plants [80–83]. Human amniotic membrane cells can also
secrete cytokines with immunoregulatory and anti-
inflammatory properties [84], angiogenic factors [85],
growth factors associated with cell proliferation and differ-
entiation, and antiapoptotic and antioxidant factors [86].
During many years, the human amniotic membrane has
been recognized for its utility in different clinical applica-
tions, like damaged tissues reconstruction and skin trans-
plants [87–89]. Interestingly, the amniotic membrane cells
possess a variety of properties attractive for clinical use,
such as the promotion of re-epithelization, the decrease of
inflammation and fibrosis, and the inhibition of angiogen-
esis and microbial growth [6, 90, 91]. Moreover, the amni-
otic membrane could be used for cancer therapy because
of its antitumoral properties [92–94].
Despite the promising properties of amniotic mem-
brane cells to heal lung diseases, at present, there are no
clinical trials registered with this purpose. Here, we de-
scribe the most outstanding characteristics of human
amniotic membrane stem cells in terms of their ability
to improve several lung injuries. Furthermore, these
properties open the field for the amniotic membrane cell
therapy for pulmonary diseases caused by COVID-19
(Fig. 2).
Human amniotic mesenchymal stromal cells
Human amniotic mesenchymal stromal cells are multi-
potent cells that can be obtained from the stromal layer
of the human amniotic membrane. Freshly isolated
hAMSCs express the classical MSCs markers, such as
CD44, CD90, CD73, and CD105 [6]. Some authors have
demonstrated the differentiation potential of hAMSCs
towards osteogenic, chondrogenic, and adipogenic line-
ages [95, 96]. Interestingly, hAMSCs display low im-
munogenicity because of their low human leukocyte
antigen (HLA)-ABC expression and the lack of HLA-DR
expression [97, 98]. Moreover, hAMSCs possess immu-
nomodulatory, anti-fibrotic, and anti-inflammatory
properties, thus allowing their use in cell therapy [99,
100]. Primarily, hAMSCs exert their therapeutic effect
by releasing soluble factors [101]. Amnion cells produce
immunomodulatory molecules, including IL-10, trans-
forming growth factor β (TGF-β), hepatocyte growth
factor (HGF), prostaglandin E2 (PGE2), and indoleamine
2,3-dioxygenase (IDO) that decrease innate and adaptive
immune cell activation [102, 103]. In addition, the im-
munomodulatory effect has also been found by cell-to-
cell contact [102, 104, 105].
Many studies reported that hAMSCs inhibit the prolif-
eration and function of T and B lymphocytes, DC, and
NK cells. Amnion cells reduced peripheral blood mono-
nuclear cells (PBMC) proliferation of in a dose-
dependent manner and suppress the cytotoxic activity of
T and NK cells [47, 106]. Magatti et al. [107] demon-
strated that hAMSCs and their conditioned medium
(hAMSC-CM) inhibit B cell proliferation and differenti-
ation by secreting factors such as prostanoids. The same
group showed the inhibitory effect of hAMSCs in DC
differentiation [108]. Additionally, amnion cells suppress
NK cytotoxicity activity against K562 monocyte cells via
IL-10 and PGE2 secretion [109]. Moreover, the NK pro-
inflammatory cytokine production (i.e., IFN-γ) was
inhibited after coculture with hAMSCs.
The anti-inflammatory effect of hAMSCs includes T
helper 1 (Th1) subset polarization to anti-inflammatory
Th22 and T regulatory (Treg) cells [47, 110]; in vitro
and in vivo inhibition of pro-inflammatory cytokine pro-
duction, such as IL-1β, IFN-γ, and TNF-α [111, 112];
and reduction of inflammatory M1 macrophages and
differentiation towards anti-inflammatory M2 macro-
phages [109, 113].
Usually, M1 are called classically activated macro-
phages, and they mainly secrete pro-inflammatory cy-
tokines. M2 are called alternatively activated
macrophages, and they mitigate inflammation and
promote wound repair [114]. When macrophage re-
sponse is predominantly M2 type, it is correlated with
fibrotic remodeling of organs, especially in the lungs.
Macrophages represent around 70% of the immune
cells in the lungs (the most abundant immune cells).
During pulmonary fibrosis both M1 and M2, macro-
phages are involved in its pathogenesis and perform
airway remodeling. MSC have been found to modu-
late the macrophage switch from an inflammatory
phenotype (M1) to an immunomodulatory phenotype
(M2) [115–117]. After this MSC-macrophage inter-
action, inflammation and tissue repair are usually re-
solved [99]. By changing macrophage phenotype, MSC
induce the secretion of anti-inflammatory cytokines,
like IL-10 and reduce the production of proinflamma-
tory cytokines, in early stages of the inflammatory
process. In addition, by inhibiting IL-1B and IL-12
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secretion, they reduce the Th1 cell activation. MSC
also secrete TSG-6 factor that inhibit NF-kB signaling
and other proinflammatory pathways. These secretions
also are responsible for M1 to M2 polarization. Exo-
somes secreted by MSC can also regulate macrophage
phenotype polarization, promoting tissue healing
[118]. As we mentioned before, in severe cases, ARDS
condition developed after COVID-19 infection. ARDS
usually lead to uncontrolled fibrosis [119]. Macro-
phage plays a central role in pulmonary fibrosis reso-
lution. Thus, by regulating macrophage polarization
and their secreted molecules, MSC is able to promote
tissue healing mainly by fibrosis reduction [120].
As MSCs, HAMSCs could be a remarkable resource
for lung injury treatment (Table 3) Recently, Li et al.
[121] showed that hAMSCs alleviate the inflammatory
microenvironment in a neonatal hyperoxic lung injury
rat model. The pro-inflammatory cytokine expression in-
cluding TNF-α, IL-6, IL-1β, and MCP-1 decreased after
hAMSC infusion. Moreover, hAMSCs reduced pulmon-
ary edema. In addition, hAMSC treatment was able to
reduce lung fibrosis and inflammation levels in a white
smoke inhalation-induced rat model [122]. In this
model, the IL-10 levels augmented after hAMSC admin-
istration via the tail vein, alleviating the pulmonary in-
flammation condition. The authors demonstrated that
the hAMSC distribution was mainly in the lung tissues.
Direct airway delivery of hAMSCs was also investigated
[123]. Authors demonstrated that hAMSCs can be suc-
cessfully atomized in vitro, maintaining the morphology
and a high cell viability. This therapy would allow a
more uniform spreading of cells throughout the lung,
simplifying the administration.
Zhang et al. [124] reported a potential hAMSC therapy
for ARDS. They demonstrated that the transfection of
Nrf2—a key transcription factor for antioxidant protein
expression—in hAMSCs enhanced their protection ef-
fects in a murine model of lipopolysaccharide (LPS)-in-
duced acute lung injury (ALI). Nrf2-transfected
hAMSCs were able to ameliorate lung fibrosis and in-
flammation, improving the cell-based therapy for ALI
and ARDS. Moreover, some authors have demonstrated
that hAMSCs release soluble factors with regulatory ac-
tions over the injury site and exert trophic actions on
host lung cells. In this way, Cargnoni et al. [49, 50] have
shown that the hAMSC-CM reduced the fibrosis pro-
gression in a bleomycin-induced lung injury mouse
model. They probed that the hAMSC-CM has the ability
to protect the lungs from dysfunction caused by fibrotic
lesions. In addition, they demonstrated that this CM re-
duced the profibrotic and inflammatory cytokine levels
as well as T-lymphocyte and macrophage infiltration in
the lungs. Notably, after comparing with CMs from
other mesodermal origin cell types (PBMCs, Jurkat cells,
human skin fibroblasts), they confirmed that the
hAMSC-CM paracrine effects are specific to amniotic
cells. These results support paracrine mechanisms of
hAMSCs in their anti-inflammatory and anti-fibrotic
effects.
Human amniotic epithelial stem cells
Human amniotic epithelial cells have advantages over
other stem cells for their use in cell therapy. HAECs de-
rive from the pluripotent epiblast, which gives rise to the
three germ layers of the embryo: endoderm, mesoderm,
and ectoderm [125]; they express markers normally
present in embryonic or germ cells and have several
characteristics that make them attractive for regenerative
medicine [126, 127]. Their differentiation potential has
been studied by several research groups. In particular,
pancreatic [127–130], pulmonary [131], hepatic [132–
138], osteogenic [139], chondrogenic [140], adipogenic
[139], neuronal [141, 142], and cardiac [127, 143] differ-
entiation has been reported. Moreover, hAECs have low
immunogenicity and anti-inflammatory properties, their
isolation is simple, and their origin does not possess eth-
ical concerns. They are obtained in great quantity, with
around 100 million cells per amnion [104, 139, 144–
147]. Also, they do not express telomerase and they are
not tumorigenic after transplantation [127].
The clinical potential of hAECs is based essentially on
their paracrine mechanisms that are capable of inducing
anti-inflammatory and immunoregulatory responses
[81]. HAECs express and secrete HLA-G that allows
allograft acceptance and correlates with a low frequency
of rejection [134]. Indeed, HLA-G modulates the im-
mune response of Treg, myeloids, and NK cells, by bind-
ing to specific receptors in immune cells [148, 149]. In
addition, hAECs express CD59 and the Fas ligand (FasL),
involved in T lymphocyte complement activity inhibition
and B lymphocyte apoptosis induction [150–152].
HAECs also secrete the migration inhibitor factor (MIF)
that prevents neutrophil and macrophage migration abil-
ity [151].
Several studies have reported the ability of hAECs to
reduce inflammatory cytokines and to release soluble
anti-inflammatory factors [104, 145, 153]. Moreover,
hAECs induce a Treg switch, altering the surrounding
microenvironment by stopping inflammation [154, 155].
Additionally, hAECs express IDO [156], an enzyme in-
volved not only in the cell cycle arrest and apoptosis of
active CD4+ and CD8+ T cells, but also in Treg differ-
entiation to resting CD4+ T cells [157]. Importantly,
hAECs are capable to block the beginning of an immune
reaction by changing the antigen-presenting function of
DC. Amniotic cells impair the DC function and matur-
ation in vitro [108]. Since the DC presented antigen will
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Table 3 Preclinical and clinical trials for lung diseases using amniotic membrane cells
Title Diseases Cell type Type of
study
Outcome Cell therapy Authors
Intratracheal transplantation of amnion-derived
mesenchymal stem cells ameliorates
hyperoxia-induced neonatal hyperoxic lung








Preclinical ✓ Reducing pulmonary
edema and inflammatory
cell infiltration
AI effect Li et al. [1]
Human amnion-derived mesenchymal stem
cells alleviate lung injury induced by white
smoke inhalation in rats
Lung injury hAMSCs Preclinical ✓ Reducing lung injury,
lung fibrosis, CT score,
and inflammation levels
AI and AF effects Cui et al. [2]
Nrf2 transfection enhances the efficacy of
human amniotic mesenchymal stem cells
to repair lung injury induced by
lipopolysaccharide
Lung injury hAMSCs Preclinical ✓ Decreasing lung injury,
lung fibrosis, and
inflammation
AI and AF effects Zhang et al
.[3]
Conditioned medium from amniotic
membrane-derived cells prevents lung
fibrosis and preserves blood gas exchanges
in bleomycin-injured mice-specificity of the
effects and insights into possible mechanisms
Lung fibrosis CM-
hAMSCs
Preclinical ✓ Decreasing lung fibrosis




IM, AI, and AF effect Cargnoni
et al. [4]
Human amnion epithelial cell transplantation
abrogates lung fibrosis and augments repair
Lung fibrosis hAECs Preclinical ✓ Reducing inflammation
and lung collagen.




Human amnion epithelial cells repair
established lung injury






AI and AF effects Vosdoganes
et al. [6]
Title Diseases Cell type Type of
study
Outcome Cell therapy Authors
Human amnion epithelial cells mediate lung
repair by directly modulating macrophage
recruitment and polarization




IM and AI effects Tan et al. [7]
Human amnion epithelial cells prevent
bleomycin-induced lung injury and preserve
lung function






IM, AF and AI effects Murphy
et al. [8]
Human amnion epithelial cells modulate the





hAECs Preclinical ✓ Modulating the pulmonary
inflammatory
✓ Reducing acute lung injury
IM effect Melville
et al. [9]
Human amnion cells reverse acute and




hAECs Preclinical ✓ Improving lung
architecture.
✓ Reducing macrophages,
DC, NK, and pro-inflammatory
cytokines.




Amnion epithelial cell-derived exosomes




Preclinical ✓ Improving tissue-to-airspace








Human amnion epithelial cells as a treatment
for inflammation-induced fetal lung injury in
sheep






First-in-human administration of allogeneic
amnion cells in premature infants with






✓ Administration was safe and
tolerated.
✓ No adverse events.
(Completed)
- Lim et al.
[13]
Human amnion cells for the prevention of
bronchopulmonary dysplasia: a protocol for






✓ Safe and adverse events.
(Recruiting)
- Baker et al.
[14]
CM-hAMSCs conditioned medium of human amniotic mesenchymal stromal cells, EXO-hAMSCs exosomes of human amniotic mesenchymal stromal cells,
hAMSCs human amniotic mesenchymal stromal cells, hAECs human amniotic epithelial cells, EXO-hAECs exosomes of human amniotic epithelial cells, DC
dendritic cells, NK natural killer cells, CT score computed tomography score
Effects: AI anti-inflammatory, AF anti-fibrotic, IM immunomodulatory
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trigger an immunotolerance response, the manipulation
of these cells is critical for stem cell therapy.
Indeed, hAECs can improve the inflammatory and fi-
brotic microenvironment that occurs in lung injuries.
Moodley et al. [131] demonstrated the anti-
inflammatory and anti-fibrogenic effect of hAECs when
transplanted into a bleomycin-induced lung injury
mouse model. Injection of hAECs reduced levels of pro-
inflammatory cytokines such as IL-1β, IL-6, TNF-α, and
TGF-β, a pulmonary fibrosis inductor. Furthermore,
these authors demonstrated that hAECs differentiate
into surfactant factors producing epithelial cells, both
in vitro and in vivo conditions. While hAECs could
adopt a type II pneumocyte phenotype, they may be able
of longer-term alveolar restitution. However, we should
consider the possibility of differentiated hAEC infection
by SARS-CoV-2. This could be a limitation that still
needs to be study. Also, this work together with a similar
one [158] showed that hAECs promote collagen deposit
degradation, since they induce an increase in metallo-
proteinases expression and an inhibition of tissue inhibi-
tors of metalloproteinases. Besides, hAECs can release
factors such as IFN-γ and MCP-1 that regulate the in-
flammatory macrophages migration to lung lesions.
HAECs increase the levels of IL-10 [159, 160]. Another
study also showed that hAEC administration modulated
the pulmonary inflammatory response after ventilation
and reduced lung injury in preterm lambs [161]. Add-
itionally, early administration of hAECs improved the pul-
monary architecture activating bronchioalveolar stem cell
niche, in a neonatal lung injury murine model [162].
Moreover, hAECs have been able to modulate LPS-
induced fetal pulmonary inflammation and to reduce pro-
inflammatory cytokines levels in a sheep model [163].
On the other hand, hAEC-derived exosomes have been
involved as modulators of the macrophage phenotype,
inducing their differentiation from pro-inflammatory M1
type to anti-inflammatory M2 type [164].
In 2015, Lim et al. [165] reported the first hAEC phase
I clinical trial, conducted in patients with chronic lung
disease. Amniotic epithelial cells were administered
intravenously at a dose of 1 million cells per kilogram
body weight, in 6 premature babies with bronchopul-
monary dysplasia (BPD). The patients were followed for
2 years. They concluded that hAEC administration is
safe and does not cause adverse effects [165]. More re-
cently, a phase I study was initiated in newborns with se-
vere BPD. Since is unlikely that 1 million cells will be
enough for a successful treatment, this study aims to
evaluate the safety of higher doses of hAECs. The au-
thors will assess the dose escalation after intravenously
administration of up to 30 million hAECs per kilogram
in 24 premature babies with BPD.
These results will be published in mid-2022, where
the authors will include a cytokine profile description
of patients after cell injection [166]. Also, other phase
I clinical trials have begun to assess the safety of allo-
geneic hAEC transplantation in different pathologies
such as ischemic stroke [167] and hepatic fibrosis
[168]. These studies will provide evidence for subse-
quent trials. Preclinical and clinical trials related to
lung disease treatment with hAECs are summarized
in Table 3.
Up to this point, the reported benefits of hAEC trans-
plantation in lung injury models make them a remark-
able resource for lung regeneration. Since hAECs reduce
inflammatory cell infiltration, fibrosis, and cytokine pro-
duction and differentiate into alveolar epithelial cells, a
COVID-19 treatment with hAECs needs to be
considered.
Non-cellular therapies for COVID-19
The ACE2 receptor or TMPRSS2 blocking in host cells
could be one way for therapeutics elaboration against
SARS-CoV2. Indeed, there are some clinically approved
drugs that target those molecules for other treatments
[169]. Antibodies against the spike protein (to block the
interaction with ACE2), or protease inhibitors against
TMPRSS2 (to prevent spike protein cleavage) may be
other possible therapies. The use of virus memory CD8+
T cells could be effective to destroy infected cells. An al-
ternative published treatment consists in the passage of
infected patient blood though affinity columns to trap
proinflammatory cytokines [170].
Other currently available clinical therapies include re-
spiratory support (mechanical ventilation, non-invasive
ventilation or invasive ventilation), non-specific antiviral
drugs (remdesivir, lopinavir-ritonavir), plasma from recov-
ered patients, and anti-inflammatory treatments such as
NSAIDs, glucocorticoids (dexamethasone), aminoquino-
lines (chloroquine and hydroxychloroquine), immunosup-
pressants, and inflammatory cytokine antagonists [171].
Chloroquine and hydroxychloroquine are old drugs
developed for the treatment of malaria. They are also
used to treat systemic lupus erythematosus and rheuma-
toid arthritis. They are both 4-aminoquinolines [172].
Both drugs present immunomodulatory properties,
prophylactic, and antiviral activity in vitro and have been
shown to effectively act against the SARS-CoV-2 [173].
Thus, several clinical trials have been triggered with
these drugs to treat and prevent COVID-19. It has been
demonstrated that hydroxychloroquine has a more po-
tential antiviral effect, so most studies are performed
with this drug instead of chloroquine [174]. All the clin-
ical trials performed until now made arise several doubts
and questions regarding the use of chloroquine and
hydroxychloroquine to treat COVID-19 patients. The
Riedel et al. Stem Cell Research & Therapy          (2021) 12:155 Page 13 of 19
studies were small and some of them report beneficial
effects [175, 176] and some harmful [177]. Since all these
reports had important limitations and they were small
trials, questions and controversy around the use of
hydroxychloroquine for COVID-19 treatment are still in
the middle of the scene. Even the FDA that on March
28, 2020, had approved its emergency use, on June 15,
2020, cancelled this authorization due to the accumula-
tion of negative data.
As dexamethasone is a glucocorticoid capable of
modulating inflammation derived from COVID-19 lung
injury, it has been specially considered as a drug treat-
ment. On July 2020, the FDA included dexamethasone
sodium phosphate to the list of drugs for temporary
compounding by outsourcing facilities and pharmacy
compounders, and it was kept on the list until now. Yet,
the effectiveness of glucocorticoids against COVID-19 is
still in doubt. The main study with dexamethasone in-
volved the participation of 11500 patients from different
UK hospitals [178]. Half of the patients received oral or
intravenous dexamethasone. Comparison was made be-
tween those receiving dexamethasone and usual therapy
and those receiving usual therapy alone. After 28 days of
treatment, dexamethasone produced one third deaths re-
duction in mechanically ventilated patients and one fifth
reduction in those with oxygen only. The mortality was
the same in patients without any breathing help, treated
or not with dexamethasone. Moreover, there was a
chance of harm after dexamethasone treatment. Before
this trial, glucocorticoids use for COVID-19 was contra-
indicated [179]. Thus, despite dexamethasone is now in-
cluded in the recommended NIH and FDA drug list to
treat COVID-19 hospitalized patients [178, 180], its use
should be cautious and carefully considered in each case.
Remdesivir is an adenosine nucleotide analogue that
acts as antiviral drug in a broad spectrum. Its emergency
use has been approved by the FDA [181] as one of the
few helpful molecules to treat COVID-19. Initially,
remdesivir was developed to combat Ebola and now
there are different clinical data reporting its therapeutic
effect against the SARS-CoV-2. One of these trials
(phase III) reported that the recovery time in hospital-
ized COVID-19 patients was shorter when remdesivir
was used [182]. On the other hand, another study found
no differences in clinical status between remdesivir and
the standard treatment [183]. Anyway, remdesivir use
was allowed by the FDA in adults and children with se-
vere COVID-19, since its effect overcome the placebo in
patients recovery time and improves general condition
of the respiratory tract. Nevertheless, high COVID-19
mortality continues to occur; thus, combinations of ther-
apeutics methods and drugs should be careful evaluated
in the future to get better results.
Other antiviral that has been tested in some clinical
trials is lopinavir-ritonavir, an HIV protease inhibitor.
However, after negative pharmacodynamic data and no
clear evidence of benefit, the NIH has recommended to
avoid it use for COVID-19 patients [184].
Administration of convalescent plasma obtained from
patients recovered from COVID-19 is a safe procedure
that seems to have no adverse effects. The main issue is
time for administration since it has to be injected as
early as possible to achieve maximum efficiency, but the
targets are severe cases [185]. However, so far all the evi-
dence regarding convalescent plasma is positive and sup-
port its use [186].
Despite the scientific community efforts to mitigate
the effects of this pandemic, treatments to control
SARS-CoV-2 virus are not yet effective. There is an ur-
gent need to find safe and effective treatments, particu-
larly in severe cases.
Perspectives on amniotic stem cells for COVID-19
Recently, COVID-19 has attracted the global scientific
community full attention. The human and economic
losses caused by the pandemic have accelerated the
search for new effective and safe therapies against
COVID-19. Stem cells, and especially human amniotic
membrane stem cells, could be considered for future
clinical research against SARS-CoV-2 virus. However, it
is necessary to develop preclinical studies and clinical
trials with proven efficacy, especially in coronavirus-
induced respiratory diseases.
In this way, the paracrine activity of hAMSCs and
hAECs could suppress the exacerbation of the immune
system in ARDS caused by the SARS-CoV-2 virus. Am-
niotic membrane cells would allow a secretion decrease
of pro-inflammatory cytokines at the lung injury focus
and would attenuate the migration of neutrophils, mac-
rophages, and lymphocytes. Removal of these inflamma-
tory mediators would probably lead to a suppression of
the cytokine storm and would prevent a multiple organ
failure progression. Moreover, hAMSCs and hAECs
could modulate the proliferation and activation of im-
mune cells, inducing a switch to an anti-inflammatory
phenotype.
Furthermore, amnion cells would not only promote
the proinflammatory environment modulation but also a
replacement of the diseased cells. In addition, human
amniotic membrane cells could counteract fibrosis by
decreasing factors for instance TGF-β [131].
Notably, the expression of HLA-G in hAMSCs and
hAECs will allow a better transplant tolerance since this
molecule acts suppressing NK cytotoxicity and modulat-
ing T cell and B cell proliferation and activity [187].
It is worthy to mention that amnion cells have a limited
expansion capacity and they may lose their beneficial
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abilities through passages. Importantly, new protocol de-
velopment would improve amniotic cell quantity and
quality for clinical use. Some of them are in progress
[138].
In summary, due to their differentiation capacity and
its undoubted immunoregulatory properties, amnion
cells therapy would be a promising treatment for
COVID-19. They will probably act dually, not only by
the prevention of cytokine storm but also by repairing
and replacing damaged tissue. These features position
human amniotic membrane stem cells as candidates to
develop new successful protocols and curative treat-
ments for COVID-19.
Conclusions
Undoubtedly, the SARS-CoV-2 virus appearance to-
gether with the COVID-19 disease has changed the
world as it was known until present. A problem of such
dimensions commits the scientific community to de-
velop quick and effective solutions, but mainly safe. It is
urgent to find successful curative treatments. For this
reason, we must first stop to analyze the pre-existing
truthful information that allows us to hypothesize about
the clinical effectiveness of possible therapies. Stem cells
represent the great hope for regenerative medicine, and
they stand out in the search of this information. In par-
ticular, due to their set of immunoregulatory, reparative,
and regenerative properties, stem cells derived from the
amnion of the human placenta should be considered for
the treatment of this type of pulmonary affections as
well as for a wide range of diseases.
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